The blood glucose level fluctuates with the fasting–feeding cycle in most animals. On feeding, the increase in postprandial blood glucose is mainly reduced by increased glucose uptake in peripheral tissues, such as liver and skeletal muscles. This process is regulated by changes in the insulin/glucagon ratio, by portal signals, and by the blood glucose concentration itself (1–3). The liver, as a glucose sensor, actively contributes to the control of postprandial blood glucose homeostasis (4). In particular, the liver takes up approximately one-third of the oral glucose load in the animal (5). In the liver, glycogen metabolism is regulated in a complex manner to maintain postprandial blood glucose homeostasis (2,6–11). In brief, two critical enzymes are directly involved in glycogen metabolism, glycogen synthase (GS) for glycogenesis and glycogen phosphorylase (GP) for glycogenolysis. The activities of GS and GP are regulated by phosphorylation/dephosphorylation events, but in opposing directions. GS is inhibited by phosphorylation at multiple sites mediated by protein kinases, such as protein kinase A and glycogen synthase kinase 3 (GSK3), and activated by dephosphorylation via glycogen synthase phosphatase (GSP). On the other hand, GP is activated by phosphorylation at a single residue near the N-terminus by phosphorylase kinase and inhibited by dephosphorylation by protein phosphatase 1 (PP1). A postprandial increase in blood glucose results in an elevated intracellular concentration of glucose that binds activated GP (GPα) and promotes its dephosphorylation and inactivation, thus releasing the allosteric inhibitory effect of GPα on GSP (8). On the other hand, glucose-6-phosphate (G6P) produced from glucose is an allosteric activator of GS, and the potency of G6P as an activator increases as GS is dephosphorylated by GSP (7). In addition, the postprandial increase of insulin stimulates GS by reducing its phosphorylation and inactivation by GSK3, at least in muscle (12). Collectively, these events converge to activate GS and inhibit GP on feeding, resulting in accumulation of liver glycogen after a meal.

PP1 plays a critical role in glucose metabolism because of its regulatory effects on glycogen metabolizing enzymes, including GS, GP, and GP kinase (9,11). The PP1 holoenzyme is composed of a catalytic subunit (PP1c) and a regulatory subunit (11). In regulating glycogen metabolism, PP1c is anchored to the glycogen particles by a group of glycogen-targeting regulatory subunits (G subunits) that modulate the activities of the glycogen metabolizing enzymes through PP1-mediated dephosphorylation. According to the GenBank database, there are seven genes encoding G subunits (PPP1R3A to PPP1R3G), all of which possess a PPI-binding domain and a glycogen-binding domain (11,13). The intricate regulation of glycogen metabolism by G subunits has been established over the past 25 years by extensive and detailed analysis of two of these proteins, GM/PPP1R3A and GL/PPP1R3B, which are expressed relatively specifically in skeletal muscle and the liver, respectively, in rodents. The importance of these two proteins in regulating glycogen metabolism was firmly established by studies with mice that had a deletion of GM/PPP1R3A (14,15), or mice with expression of a deregulated form of...
FIG. 1. PPP1R3G is regulated in the fasting–feeding cycle. 

A: Male C57BL/6 J mice at 8 weeks of age were killed in the constant feeding state or after 6-h (from 0:00 to 6:00 A.M.) or 12-h fasting (from 6:00 P.M. to 6:00 A.M. the next day). Liver PPP1R3G and FGF21 mRNA levels were measured by RT-qPCR (n = 4 mice/group). Fold change of each gene compared with actin is shown as mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001 as comparison with the feeding group.

B: Liver protein samples in A were used in immunoblotting to detect protein levels of PPP1R3G and tubulin.

C: PPP1R3G mRNA levels in brain, white adipose tissue, and skeletal muscle in feeding or after 12-h fasting.

D: Male C57BL/6 J mice at 8 weeks of age were killed in the feeding state, after 12-h fasting, or after refeeding for the time as indicated. Liver PPP1R3G mRNA level was measured by RT-qPCR (n = 4 mice/group). Statistics analysis is done by comparing the refeeding group with the fasting group.

E: Liver samples in D were used in immunoblotting with the antibodies as indicated (top). Quantitation of the data is shown (bottom). **P < 0.01 between the groups as indicated.

F: Primary hepatocytes isolated from overnight-fasted mice were serum-starved for 10 h and then treated with 100 nmol/L glucagon or 1 μmol/L...
GL/PPP1R3B (16). Mice with heterozygous deletion of PTG/R5/PPP1R3C had reduced glycogen levels in several tissues and became glucose intolerant and insulin resistant as they aged (17). In contrast, little is known about the physiologic function of other G subunits and the reason for the plethora of genes encoding this group of proteins. Furthermore, how G subunits are coordinated with the fasting–feeding cycle to control postprandial glucose homeostasis is largely unknown. In this study, we demonstrate that PPP1R3G, a previously uncharacterized glycogen-targeting regulatory subunit of PP1, is actively involved in the control of blood glucose homeostasis by regulating hepatic glycogenesis in a manner closely coordinated with the fasting–feeding cycle.

RESULTS
PPP1R3G is regulated by the fasting–feeding cycle. To gain a global view of genes regulated by fasting in the liver, we examined genes of the whole mouse genome by mRNA microarray (Supplementary Table 1). Unexpectedly, PPP1R3G, a predicted glycogen-targeting regulatory subunit of PP1 (13), was found to be highly upregulated by fasting. By RT-PCR analysis, PPP1R3G was expressed in many mouse tissues with a relatively high level in liver, brain, lung, white adipose, and adrenal gland (Supplementary Fig. 1A). As confirmed by real-time RT-PCR, PPP1R3G mRNA level was increased to ~12-fold and 35-fold in the liver after fasting for 6 and 12 h, respectively (Fig. 1A). As a positive control, FGF21, which was reported to be highly induced by fasting (24), was also elevated in our experiment (Fig. 1A). The protein level of PPP1R3G was upregulated consistently by fasting in the mouse liver (Fig. 1B) using an antibody generated in our laboratory (Supplementary Fig. 1B and C). However, none of the other three glycogen-related genes, including brain, white adipose, and skeletal muscle, had an induction of PPP1R3G on fasting at the mRNA and protein levels (Fig. 1C, Supplementary Fig. 1D). PPP1R3G mRNA level was quickly reduced after refeeding, reaching the prefasting level after 2-h feeding (Fig. 1D). PPP1R3G protein was also significantly downregulated after refeeding (Fig. 1E). Collectively, these data demonstrate that PPP1R3G is a cyclic gene that changes along with the fasting–feeding cycle in the mouse liver.

To identify the molecular mechanism that underlies the regulation of PPP1R3G expression, we analyzed the effects of three major signals/hormones—glucagon, dexamethasone, and insulin—that have been shown by others to regulate other fasting-related gene expression (25). In primary mouse hepatocytes, treatment of glucagon or dexamethasone alone could not significantly elevate PPP1R3G at both protein and mRNA levels (Fig. 1F and G). However, when the cells were treated with these two factors together, PPP1R3G was significantly elevated at both protein and mRNA levels (Fig. 1F and G). We next analyzed the activity of a putative PPP1R3G promoter that contained a 2-kb fragment in the 5′ region upstream of PPP1R3G coding region. In concert with the change at the protein and mRNA levels, the PPP1R3G promoter activity was also significantly induced by dexamethasone and glucagon (Fig. 1F). We found that PPP1R3G mRNA level and PPP1R3G promoter activity were both reduced by insulin (Fig. 1H and J), indicating that insulin signaling likely plays a role in turn off PPP1R3G expression during refeeding.

Interaction of PPP1R3G with the catalytic subunit of PP1 and GS. To confirm whether PPP1R3G is indeed a glycogen-related regulatory subunit of PP1, we first investigated whether PPP1R3G and PP1c were colocalized in the cell. When the catalytic subunit of PP1 (the α isoform of PP1c, the same for other experiments used in Fig. 2) was expressed alone, it was localized in the cytoplasm and nuclei (Fig. 2A), consistent with a previous report (26). However, when coexpressed with PPP1R3G, the cytoplasmic dexamethasone (Dex) for 12-h reagents as indicated for 12 h. The cell lysate was used in immunoblotting with the antibodies as indicated. G and H: Effect of glucagon, Dex, and insulin on PPP1R3G mRNA level. Primary hepatocytes isolated from overnight-fasted mice were serum-starved for 10 h, treated with 100 nmol/L glucagon, 1 μmol/L Dex, or 100 nmol/L insulin as indicated for 12 h, followed by RT-qPCR. The fold change of PPP1R3G mRNA in control group is set to 1. Data are shown as mean ± SD. *P < 0.05 and ***P < 0.001 compared with the untreated control. WAT, white adipose tissue.

GL/PPP1R3B (16). Mice with heterozygous deletion of PTG/R5/PPP1R3C had reduced glycogen levels in several tissues and became glucose intolerant and insulin resistant as they aged (17). In contrast, little is known about the physiologic function of other G subunits and the reason for the plethora of genes encoding this group of proteins. Furthermore, how G subunits are coordinated with the fasting–feeding cycle to control postprandial glucose homeostasis is largely unknown. In this study, we demonstrate that PPP1R3G, a previously uncharacterized glycogen-targeting regulatory subunit of PP1, is actively involved in the control of blood glucose homeostasis by regulating hepatic glycogenesis in a manner closely coordinated with the fasting–feeding cycle.

RESULTS
PPP1R3G is regulated by the fasting–feeding cycle. To gain a global view of genes regulated by fasting in the liver, we examined genes of the whole mouse genome by mRNA microarray (Supplementary Table 1). Unexpectedly, PPP1R3G, a predicted glycogen-targeting regulatory subunit of PP1 (13), was found to be highly upregulated by fasting. By RT-PCR analysis, PPP1R3G was expressed in many mouse tissues with a relatively high level in liver, brain, lung, white adipose, and adrenal gland (Supplementary Fig. 1A). As confirmed by real-time RT-PCR, PPP1R3G mRNA level was increased to ~12-fold and 35-fold in the liver after fasting for 6 and 12 h, respectively (Fig. 1A). As a positive control, FGF21, which was reported to be highly induced by fasting (24), was also elevated in our experiment (Fig. 1A). The protein level of PPP1R3G was upregulated consistently by fasting in the mouse liver (Fig. 1B) using an antibody generated in our laboratory (Supplementary Fig. 1B and C). However, none of the other three glycogen-related genes, including brain, white adipose, and skeletal muscle, had an induction of PPP1R3G on fasting at the mRNA and protein levels (Fig. 1C, Supplementary Fig. 1D). PPP1R3G mRNA level was quickly reduced after refeeding, reaching the prefasting level after 2-h feeding (Fig. 1D). PPP1R3G protein was also significantly downregulated after refeeding (Fig. 1E). Collectively, these data demonstrate that PPP1R3G is a cyclic gene that changes along with the fasting–feeding cycle in the mouse liver.

To identify the molecular mechanism that underlies the regulation of PPP1R3G expression, we analyzed the effects of three major signals/hormones—glucagon, dexamethasone, and insulin—that have been shown by others to regulate other fasting-related gene expression (25). In primary mouse hepatocytes, treatment of glucagon or dexamethasone alone could not significantly elevate PPP1R3G at both protein and mRNA levels (Fig. 1F and G). However, when the cells were treated with these two factors together, PPP1R3G was significantly elevated at both protein and mRNA levels (Fig. 1F and G). We next analyzed the activity of a putative PPP1R3G promoter that contained a 2-kb fragment in the 5′ region upstream of PPP1R3G coding region. In concert with the change at the protein and mRNA levels, the PPP1R3G promoter activity was also significantly induced by dexamethasone and glucagon (Fig. 1F). We found that PPP1R3G mRNA level and PPP1R3G promoter activity were both reduced by insulin (Fig. 1H and J), indicating that insulin signaling likely plays a role in turn off PPP1R3G expression during refeeding.

Interaction of PPP1R3G with the catalytic subunit of PP1 and GS. To confirm whether PPP1R3G is indeed a glycogen-related regulatory subunit of PP1, we first investigated whether PPP1R3G and PP1c were colocalized in the cell. When the catalytic subunit of PP1 (the α isoform of PP1c, the same for other experiments used in Fig. 2) was expressed alone, it was localized in the cytoplasm and nuclei (Fig. 2A), consistent with a previous report (26). However, when coexpressed with PPP1R3G, the cytoplasmic dexamethasone (Dex) for 12-h reagents as indicated for 12 h. The cell lysate was used in immunoblotting with the antibodies as indicated. G and H: Effect of glucagon, Dex, and insulin on PPP1R3G mRNA level. Primary hepatocytes isolated from overnight-fasted mice were serum-starved for 10 h, treated with 100 nmol/L glucagon, 1 μmol/L Dex, or 100 nmol/L insulin as indicated for 12 h, followed by RT-qPCR. The fold change of PPP1R1E3G mRNA in control group is set to 1. Data are shown as mean ± SD. *P < 0.05 and ***P < 0.001 compared with the untreated control. WAT, white adipose tissue.
FIG. 2. Interaction of PPP1R3G with PP1c and GS. A: PPP1R3G colocalizes with PP1c in the cytoplasm. Hela cells were transfected with Myc-PP1c alone (top) or together with Flag-tagged PPP1R3G (bottom), followed by immunostaining and confocal analysis. Arrows indicate apparent colocalization of PPP1R3G with PP1c. B: Endogenous PPP1R3G colocalizes with endogenous PP1c in the cytoplasm. Primary hepatocytes isolated from overnight-fasted mice were used in immunostaining with the antibodies as indicated. Arrows indicate apparent colocalization of PPP1R3G with PP1c. C: Interaction of PPP1R3G with PP1c as analyzed by GST pull-down assay. HEK293T cells were transiently transfected with Myc-tagged PP1c. Twenty-four hours after transfection, cell lysate was incubated with GST proteins as indicated (top, Coomassie-stained gel), and the GST pull-down product was used in immunoblotting (bottom). D: In vivo interaction of overexpressed PPP1R3G with PP1c. HEK293T cells were transiently transfected with Flag-tagged PPP1R3G, Flag-tagged PPP1R3C, and Myc-tagged PP1c as indicated. Twenty-four hours after transfection, cell lysate was used in immunoprecipitation (IP) and immunoblotting (IB) with the antibodies as indicated. E: In vitro interaction of PPP1R3G with PP1c. Purified GST, GST-PPP1R3G, and His-PP1c (top, Coomassie-stained gel) were incubated as indicated, followed by GST pull-down and immunoblotting (bottom). F: Interaction of endogenous PPP1R3G with PP1c. Male C57Bl/6 J mice at 8 weeks of age were killed in the feeding state or after 12 h fasting. Liver protein was used in IB and IP. G: PPP1R3G is localized at the GEPs. HepG2 cells were transfected using the plasmids as indicated. Twenty-four hours after transfection, the cells were homogenized and post-nuclear supernatant was used in fractionation and IB with an anti-Flag antibody. (A high-quality digital representation of this figure is available in the online issue.)
localization of PP1c in the cytoplasm was significantly increased with a profound colocalization with PPP1R3G (Fig. 2A). Endogenous PP1c and endogenous PPP1R3G also had a profound cytoplasmic colocalization in primary hepatocytes isolated from overnight-fasted mouse (Fig. 2B).

We used GST pull-down and coimmunoprecipitation assays to analyze the interaction between the two proteins. We found that the purified PPP1R3G GST fusion protein could pull down PP1c in vitro (Fig. 2C). At the in vivo level, these two proteins could also interact with each other in a coimmunoprecipitation assay when they were coexpressed in HEK293T cells (Fig. 2D). As a positive control, a known PP1 regulatory subunit, PPP1R3C (27), could also interact with PP1c in the assay (Fig. 2D). Next, we explored whether the interaction is direct. We found that the purified His-tagged PP1c protein was able to interact with the purified PPP1R3G GST fusion protein in vitro (Fig. 2E). At the animal level, the interaction of endogenous PPP1R3G with endogenous PP1c in the liver of fasted mice was confirmed (Fig. 2F). In addition, the β isoform of PP1c was also able to colocalize with PPP1R3G (Supplementary Fig. 2A) and interact with PPP1R3G (Supplementary Fig. 2B and C).

To determine whether PPP1R3G is localized in the glycogen-enriched pellet (GEP) fraction within the cell, we fractionated PPP1R3G-transfected HepG2 cells by ultracentrifugation to obtain cytosolic and GEP fractions from post-nuclear supernatant (28). PPP1R3G could be found in both post-nuclear supernatant and GEP fractions (Fig. 2G), and deletion of the predicted glycogen-binding motif led to complete loss of GEP localization of PPP1R3G (Fig. 2G). Furthermore, PPP1R3G could be detected in the supernatant fraction after GEP fractions were treated with α-amylase and sedimentation, further indicating glycogen association of PPP1R3G (Supplementary Fig. 2D).

**PPP1R3G stimulates glycogen synthesis in hepatocytes.**

We next investigated the functional role of PPP1R3G in glycogen synthesis. We constructed an adenovirus that could overexpress PPP1R3G in mouse hepatocytes (Fig. 3A). In vivo staining of glycogen in the primary hepatocytes and HepG2 cells revealed that the cells with high expression of PPP1R3G were associated with an increase of glycogen content (Supplementary Fig. 3A and B). Direct measurement of glycogen also demonstrated that PPP1R3G dose-dependently increased the glycogen content in primary hepatocytes (Fig. 3B). However, when the predicted glycogen binding motif of PPP1R3G was deleted, the glycogen-stimulating effect was completely abrogated (Supplementary Fig. 3B and C).

Although overexpression of PPP1R3G itself was able to elevate glycogen content in the absence of glucose in the cultured cells (Fig. 3C), PPP1R3G-induced elevation of glycogen synthesis was more effective with increasing the level of glucose than the cells without PPP1R3G overexpression (Fig. 3C), indicating that PPP1R3G-regulated glycogenesis is dependent on available glucose substrate. On the other hand, it has been proposed that glycogen-targeting subunits of PP1 are involved in insulin regulation of glycogen synthesis (29,30). We found that insulin could increase glycogen in primary hepatocytes with or without PPP1R3G overexpression (Fig. 3D). Meanwhile, forskolin could reduce glycogen content in the presence of overexpressed PPP1R3G (Fig. 3E). To further confirm that PPP1R3G is able to elevate glycogenesis, we used small interfering RNA strategy to silence the expression of endogenous PPP1R3G. Two of three shRNA sequences could significantly downregulate PPP1R3G expression at both the mRNA level (Fig. 3F) and protein level (Fig. 3G). Consistently, these two shRNA sequences reduced glycogen content in primary hepatocytes (Fig. 3H). We also analyzed glucose dependence of PPP1R3G shRNA (9062) on glycogenesis and found that PPP1R3G knockdown could reduce glycogen content at various glucose concentrations (Fig. 3I). Collectively, our data indicate that PPP1R3G is a regulatory subunit of PP1 to facilitate stimulation of glycogen synthesis in hepatocytes.

**In vivo function of PPP1R3G on glycogen synthesis and blood glucose homeostasis.**

We next analyzed the in vivo function of PPP1R3G on the regulation of glycogen synthesis and blood glucose homeostasis. We first used recombinant adenovirus to deliver PPP1R3G-expressing plasmid to the mouse liver. Previous studies have shown that intravenous administration of adenoviral vectors in mice almost exclusively targets the transgene to the liver (31). C57BL/6 J mice were injected with the control or PPP1R3G-expressing adenovirus. Evaluation of aminotransferases in the serum indicates that the PPP1R3G-expressing adenovirus did not cause apparent functional damage to the liver (Supplementary Fig. 4A).

By immunoblotting assay and real-time RT-PCR, we confirmed that the PPP1R3G-expressing adenovirus was able to drive abundant expression of PPP1R3G in the mouse liver (Fig. 4A and B). The PPP1R3G mRNA level was elevated by the adenovirus to ~12-fold (Fig. 4B), comparable to the level induced by fasting (Fig. 1A). Consistent with the observation with cultured hepatocytes, the liver glycogen content of mice infected with PPP1R3G-expressing adenovirus was significantly elevated, reaching to approximately threefold higher than in control animals (Fig. 4C). We next performed glucose tolerance tests with the animals. PPP1R3G overexpression led to a decrease in fasting blood glucose level and an increase in glucose clearance rate (Fig. 4D), with the area under curve (AUC) of glucose tolerance test reducing by ~20% (Fig. 4E). However, insulin tolerance test revealed no difference between the two groups of mice (Fig. 4F), indicating that insulin sensitivity is not altered by PPP1R3G overexpression in vivo. Collectively, these data suggest that overexpressed PPP1R3G could increase clearance of blood glucose likely by increasing conversion of blood glucose into liver glycogen.

To support our hypothesis that fasting-induced PPP1R3G is involved in postprandial blood glucose homeostasis, we injected the mice with recombinant adenovirus that contains shRNA specific for PPP1R3G, and the adenovirus did not cause apparent functional damage to the liver (Supplementary Fig. 4). When PPP1R3G was silenced in the liver, the fasting-induced PPP1R3G expression was largely abrogated (Fig. 5A). After a 12-h fast, the mice infected with PPP1R3G shRNA adenovirus had less hepatic glycogen content than the control mice (Fig. 5B). Refeeding for 1 h increased the hepatic glycogen content, and such increase was significantly attenuated when PPP1R3G was downregulated (Fig. 5B). Most important, the postprandial blood glucose clearance rate was altered when PPP1R3G expression was silenced. The glucose tolerance test revealed that the glucose clearance rate was significantly decreased in PPP1R3G-downregulated mice in comparison with the control animals (Fig. 5C), with AUC increasing by ~50% (Fig. 5D). However, insulin sensitivity did not seem to be affected by downregulation of PPP1R3G (Fig. 5E).
To provide further evidence that PPP1R3G is directly involved in postprandial hepatic glycogenesis, we analyzed the amount of newly synthesized glycogen in the mouse by using 3H-labeled glucose as a tracer. Mice injected with control or PPP1R3G-shRNA adenovirus were fasted for 12 h, followed by intraperitoneal injection of glucose containing a trace amount of 3H-glucose. The mice were killed 1 h later, and the isolated liver glycogen was subjected to radioactivity measurement. As shown in Fig. 5F, the amount of newly synthesized glycogen in the liver was reduced to ~50% by PPP1R3G knockdown. These data collectively indicate that PPP1R3G is directly involved in postprandial regulation of hepatic glycogenesis.

**PPP1R3G modulates the activity of GS in coordination with the fasting–refeeding cycle.** Because GS and GP are two key enzymes modulated by PP1-mediated dephosphorylation, we investigated whether PPP1R3G could influence the activities of these two enzymes. When PPP1R3G was overexpressed by adenovirus in the liver in the fed state, GS activity was markedly elevated (Fig. 6A), whereas GP activity was not affected (Fig. 6B). Because our results indicate that PPP1R3G mainly acts on GS instead of GP to regulate glycogenesis in the liver, we next focused on analyzing the effect of PPP1R3G on GS activity during the fasting–feeding cycle (Fig. 6C). In the fasting–feeding cycle, GS activity decreased ~50% after fasting for 6 h and slightly elevated to the unfasted level in 24 h. However, GS activity
was robustly increased on refeeding for 1 to 2 h and subsequently declined to a very low level in 12 h. This phenomenon is consistent with previous reports (32–34). We next investigated how PPP1R3G knockdown could affect GS activity during the fasting–feeding cycle (Fig. 6C). We found that the major effect of PPP1R3G knockdown is to reduce GS activity around the fasting–refeeding transition. During constant feeding and at early fasting or refeeding for 12 h, PPP1R3G knockdown only slightly reduced GS activity. However, the GS activity was decreased to 40% in the liver at fasting for 24 h and at refeeding for 1 to 2 h when PPP1R3G was silenced. Accordingly, we found that the phosphorylation level of GS at Ser641 in mouse livers was very high during fasting and robustly reduced by refeeding for 1 to 2 h (Supplementary Fig. 5), consistent with the observation that GS activity was robustly stimulated by refeeding (Fig. 6C). Furthermore, GS phosphorylation at Ser641 was elevated by PPP1R3G knockdown during refeeding (Supplementary Fig. 5), consistent with the finding that GS activity was reduced by PPP1R3G knockdown (Fig. 6C). Collectively, these data indicate that PPP1R3G mainly functions during the period of fasting–refeeding transition to regulate GS activity.

It is noteworthy that PPP1R3G is not the only glycogen-targeting regulatory subunit of PP1 to regulate hepatic glycogen synthesis. In addition to PPP1R3G, other glycogen-targeting regulatory subunits of PP1, such as PPP1R3B, 3C, 3D, and 3E, are also expressed in the liver (13,37). In the fed state, G/P/PPP1R3B accounts for ~60% of GS phosphatase activity, and the PPP1R3C, 3D, and 3E account for the remaining activity (13,37). To investigate how these glycogen-targeting regulatory subunits orchestrate to control hepatic glycogenesis, we analyzed the expression patterns of PPP1R3B, 3C, 3D, 3E, and 3G at different times during fasting and refeeding (Fig. 6D). The mRNA of PPP1R3A and PPP1R3F was hardly detectible in the liver in our experiment (data not shown). Fasting for 24 h could reduce the mRNA levels of PPP1R3B, 3C, and 3D, whereas refeeding for 1 h significantly elevated the mRNA levels of these three subunits. The mRNA level of PPP1R3E seemed to be unaffected by fasting and refeeding. In contrast, the expression of PPP1R3G was markedly stimulated by fasting and rapidly reduced by refeeding. Taken together, these data indicate that the expression pattern of PPP1R3G differs from other glycogen-targeting subunits during the fasting–feeding cycle.

**DISCUSSION**

So far there are seven glycogen regulatory subunits (G subunits) of PP1 in mammals, PPP1R3A to PPP1R3G (11,13). Phylogenetic tree analysis reveals that although all seven human subunits and their rodent orthologs possess known or putative PP1-interacting and glycogen-binding domains, none of the subunits shares more than 40% amino acid identity, suggesting that each subunit may serve a nonredundant function in mammals (13). In this study, we demonstrate that PPP1R3G is indeed a glycogen-targeting regulatory subunit of PP1. At the cellular level, PPP1R3G is associated with glycogen pellet, interacts with the catalytic subunit of PP1, and regulates GS activity. At the animal level, PPP1R3G is able to regulate glycogen synthesis in

---

**FIG. 4.** PPP1R3G overexpression accelerates postprandial blood glucose clearance in the mouse. A: Overexpression of PPP1R3G in the mouse liver. Male C57BL/6 J mice at 8 weeks of age were infected with adenovirus Ad-GFP or Ad-PPP1R3G (containing a Flag tag at N-terminus) via tail-vein injection. At 9 days post-infection, animals were killed in the fed state. The livers were used in immunoblotting with antibodies as indicated. B: PPP1R3G mRNA level in the liver was measured by RT-qPCR (n = 6 mice/group) from the samples in A. Data are shown as mean ± SD. ***P < 0.001 between the two groups. C: Liver glycogen content from samples in A were measured (n = 8 for Ad-GFP and n = 9 for Ad-PPP1R3G). D–F: Glucose tolerance test (for D) and insulin tolerance test (for F) were performed at 4 days post-infection (n = 7 for Ad-GFP and n = 8 for Ad-PPP1R3G). Mice were fasted for 4 h before glucose injection or insulin injection. Bar graph (E) represents the AUC calculated from the glucose tolerance test. Data are shown as mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001 between the two groups of mice.
The liver and modulate blood glucose homeostasis. Fasting glucose level is reduced when PPP1R3G is overexpressed in the liver. On the other hand, hepatic silencing of PPP1R3G reduces postprandial elevation of GS activity and slows down postprandial clearance of blood glucose. Collectively, our data reveal for the first time that PPP1R3G is a functional regulatory subunit of PP1 and plays a role in regulating GS activity, hepatic glycogenesis, and postprandial blood glucose homeostasis.

One of the most intriguing findings of this study is that PPP1R3G is involved in the regulation of hepatic glycogenesis in a manner coupled to the fasting–feeding cycle and distinct from other G subunits, especially GL/PPP1R3B, a major protein that regulates liver glycogen metabolism. It was originally reported in the early 1970s that liver GSP is inhibited by GPa (38), explaining why GS becomes inhibited while GP is activated. It was later found that glucose binds to GPa and promotes its dephosphorylation and inactivation, thereby terminating the inhibition on GSP by GPa so that glycogen can be resynthesized when blood glucose is high after a meal (8). In the mid-1980s it became clear that a form of PP1 was the major hepatic GSP in the fed state and that this enzyme was inhibited allosterically by GPa (39–41). The liver GSP in the fed state was later purified and shown to be a complex of GL/PPP1R3B with PP1 (42). The allosteric binding site for GPa was found to be located on the GL/PPP1R3B subunit, and not the PP1 catalytic subunit (42), and the GPa-binding site was located at the extreme C-terminus of GL/PPP1R3B (43,44). Mice that expressed GL/PPP1R3B(Y284F) mutant that could not by...
FIG. 6. PPP1R3G modulates the activity of GS in coordination with the fasting–refeeding cycle. A and B: Liver GS and GP activities were measured from the samples as of Fig. 4A. C: Male C57BL/6 J mice at 8 weeks of age were infected with shRNA adenovirus as indicated via tail-vein injection. Seven days after infection, animals were killed in constant feeding state, after fasting, or after refeeding for the time as indicated (n = 4 or 5 mice/group). Liver GS activity is shown as mean ± SE. *P < 0.05 and **P < 0.01. The numbers above the bars of Ad-scrambled-shRNA group mark the actual GS activity. The numbers above the bars of Ad-PPP1R3G group represent the percentage decrease of GS activity in this group in comparison with the control group, respectively. D: Expression patterns of PPP1R3G and other glycogen-targeting regulatory subunits of PP1 in the liver during fasting and refeeding. The liver samples of mice (n = 4 mice/group) with fasting and refeeding for different amounts of time were used to determine the mRNA levels of PPP1R3B, 3C, 3D, 3E, and 3G by RT-qPCR. Data are shown as mean ± SD. *P < 0.05 and **P < 0.01 compared with the unfasted group. E: Simplified model to depict the expression patterns of glycogen-targeting regulatory subunits of PP1 determine how these subunits contribute to GS activity and liver glycogenesis at different phases of the fasting–feeding cycle. Because of its unique expression pattern, PPP1R3G plays a major role in regulating hepatic glycogenesis during the fasting–feeding transition. For simplicity purposes, the expression pattern of PPP1R3E is not included because its expression level is not changed during the fasting–feeding cycle in the liver.
inhibited by GPa consistently showed enhanced activation of hepatic GS and conversion of blood glucose into hepatic glycogen (16). This information has been exploited to develop small molecule inhibitors to disrupt the interaction between GPa and GL/PPP1R3B to enhance the conversion of blood glucose to hepatic glycogen (45). It is noteworthy that inhibition by GPa is the unique feature of GL/PPP1R3B not shared by any other G subunit, including PPP1R3G. We propose that the lack of a GPa binding site in PPP1R3G, and therefore presumably the lack of allosteric inhibition of the PP1-PPP1R3G complex by GPa, comprises a crucial difference from the PP1-PPP1R3B complex. Such a difference may explain why PPP1R3G is needed at the fasting–feeding transition. During starvation, when the glucagon/insulin ratio is high, GP would be expected to be largely in the active form. At the early stage of the fasting–feeding transition when GPa has not been inactivated, one would not want GPa to inhibit GSP activity; otherwise, GS activity would not be activated efficiently and the glucose could not be rapidly used to replenish hepatic glycogen after a meal. At the early stages of the fasting–feeding transition, the expression of PPP1R3G reaches its maximum while GL/PPP1R3B expression is minimal (Fig. 6D). Thus, PP1-PPP1R3G complex may function as the major GSP at this time. In the normally fed state, the PP1-PPP1R3B complex may replace the PP1-PPP1R3G complex as the major GSP so that the important allosteric regulation by GPa can be introduced. Consistent with our model, we found that GL/PPP1R3B accounts for ~60% of GSP activity in the fed state (13,37). Because of the functional and expression difference between PPP1R3G and other G subunits, especially GL/PPP1R3B in the liver, it is expected that the major physiologic mission of PPP1R3G is to ensure rapid activation of GS and rapid glycogen synthesis in the liver shortly after a meal, subsequently contributing to postprandial glucose clearance (Fig. 6E).

When feeding triggers stimulation of GS activity via different means, such as a rapid increase of blood glucose and insulin levels, insulin-mediated phosphorylation and inactivation of GSK-3, translocation of GS to the cellular periphery, conversion of intracellular glucose to G6P, and portal signals (2,5,10,11), the PPP1R3G-mediated GS activity would rapidly lead to hepatic glycogenesis and removal of postprandial blood glucose. In a simplistic way, and as judged by the increase of AUC in the glucose tolerance test in PPP1R3G knockdown mice (Fig. 5D), the reduction of postprandial newly synthesized liver glycogen (Fig. 5P), and the decrease of GS activity by these mice shortly after refeeding (Fig. 6C), it can be estimated that at least 50% of the postprandial hepatic glycogen synthesis and the reduction in blood glucose are mediated by a PPP1R3G-mediated mechanism. In humans, hepatic glycogenesis is reduced in diabetic patients, and genetic variations of genes involved in glycogen metabolism have been found in diabetic patients (46–48). In mice, although Suzuki et al. (14) reported that deletion of GM/PPP1R3A had no obvious defects, other reports indicate that deletion of GM/PPP1R3A leads to increased weight gain, obesity, glucose intolerance, and insulin resistance (15,49). Hepatic expression of a C-terminus–truncated form of GM/PPP1R3A in streptozotocin-induced diabetic rats can reverse hyperglycemia and hyperphagia (50). Mice that expressed the GL/PPP1R3B(Y284F) mutant that could not be inhibited by GPa had an enhanced activation of hepatic GS activity and improved glucose tolerance (16). In addition, heterozygous deletion of PTG/PPP1R3C in mice led to glucose intolerance, hyperinsulinemia, and insulin resistance with aging (17). Therefore, the next challenge will be to determine whether alteration of PPP1R3G is associated with insulin resistance and type 2 diabetes and whether modulation of PPP1R3G can serve as a new strategy to improve glucose metabolism.

**ACKNOWLEDGMENTS**

This work was supported by research grants from the Chinese Academy of Sciences (KSCXZ-EW-R-08), the National Natural Science Foundation of China (30830037 and 81021002), and the Ministry of Science and Technology of China (2007CB947100 and 2006CB943900) to Y.C. The work was also supported by the Ministry of Science and Technology of China (2010CB529506 to Y.P. and Z.W.) and the National Natural Science Foundation of China (30971660 to Y.P.).

No potential conflicts of interest relevant to this article were reported.

XL performed the experiments, analyzed data, and wrote the article. Y.Z., X.R., X.J., L.Z., X.W., and Q.D. performed the experiments. W.L., Y.P., and Z.W. contributed the reagents, material, and analysis tools. Y.C. analyzed data, wrote the article, and conceived and designed the experiments.

The authors thank Drs. Peter J. Roach and Anna A. DePaoli-Roach at the Indiana University School of Medicine for valuable suggestions and discussion; Qiong Wang and Lei Jiang at the Institute for Nutritional Sciences (INS) for technical assistance with adenovirus purification; Shanshan Pang and Haiqing Tang at the INS for assistance with tail-vein injection; Ting Mao and Mengle Shao at the INS for assistance with hepatocyte isolation; and Dr. Yong Liu at the INS for providing recombinant GFP adenovirus.

**REFERENCES**

1. Cherrington AD. Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes 1999;48:1198–1214
2. Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J 2008;414:1–18
3. Shoemaker WC, Yanof HM, Turk LN 3rd, Wilson TH. Glucose and fructose absorption in the unanesthetized dog. Gastroenterology 1963;44:654–663
4. Shoemaker WC, Elwyn DH. Liver: functional interactions within the intact animal. Annu Rev Physiol 1969;31:227–268
5. Moore MC, Cherrington AD, Wasserman DH. Regulation of hepatic and peripheral glucose disposal. Best Pract Res Clin Endocrinol Metab 2003; 17:343–364
6. Hers HG. The control of glycogen metabolism in the liver. Annu Rev Biochem 1976;45:167–189
7. Larner J, Roach PJ, Huang LC, Brooker G, Murad F, Hazen R. Hormonal control of glycogen metabolism. Adv Exp Med Biol 1979;111:103–123
8. Nuttall FQ, Gilboe DP, Gannon MC, Niewoehner CB, Tan AW. Regulation of glycogen synthesis in the liver. Am J Med 1988;85(5A):77–85
9. Brady MJ, Saltiel AR. The role of protein phosphatase-1 in insulin action. Recent Prog Horm Res 2001;56:157–173
10. Ferrer JC, Favre C, Gonnis RR, et al. Control of glycogen deposition. FEBS Lett 2003;546:127–132
11. Ceulemans H, Bollen M. Functional diversity of protein phosphatase-1, a cellular economizer and reset button. Physiol Rev 2004;84:1–39
12. Lawrence JC Jr, Roach PJ. New insights into the role and mechanism of glycogen synthase activation by insulin. Diabetes 1997;46:541–547
13. Munro S, Ceulemans H, Bollen M, Diplexcito J, Cohen PT. A novel glycogen-targeting subunit of protein phosphatase 1 that is regulated by insulin and shows differential tissue distribution in humans and rodents. FEBS J 2005;272:1478–1489
14. Suzuki Y, Lanner C, Kim JH, et al. Insulin control of glycogen metabolism in knockout mice lacking the muscle-specific protein phosphatase PPP1G/RGL. Mol Cell Biol 2001;21:2683–2694
15. Paterson J, Kelsall IR, Cohen PT. Disruption of the striated muscle glycogen-targeting subunit of protein phosphatase 1: influence of the genetic background. J Mol Endocrinol 2008;40:47–59

16. Kelsall IR, Rosenzweig D, Cohen PT. Disruption of the allosteric phosphorylase a regulation of the hepatic glycogen-targeted protein phosphatase 1 improves glucose tolerance in vivo. Cell Signal 2009;21:1123–1134

17. Crosson SM, Khan A, Printen J, Pessin JE, Saltiel AR. PTG gene deletion causes impaired glycogen synthesis and developmental insulin resistance. J Clin Invest 2003;111:1423–1432

18. Feng L, Xie X, Ding Q, et al. Spatial regulation of Raf kinase signaling by RKTG. Proc Natl Acad Sci U S A 2007;104:14348–14353

19. Wang Q, Jiang L, Wang J, et al. Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice. Hepatology 2009;49:1166–1175

20. Worby CA, Gentry MS, Dixon JE. Malin decreases glycogen accumulation by promoting the degradation of protein targeting to glycogen (PTG). J Biol Chem 2008;283:4069–4076

21. Lo S, Russell JC, Taylor AW. Determination of glycogen in small tissue samples. J Appl Physiol 1970;28:234–236

22. Thomas JA, Schleider KK, Larner J. A rapid filter paper assay for UDP-glucose:glycogen glucosyltransferase, including an improved biosynthesis of UDP-14C-glucose. Anal Biochem 1968;25:486–499

23. Gilboe DP, Larson KL, Nuttall FQ. Radioactive method for the assay of glycogen phosphorylases. Anal Biochem 1972;47:29–27

24. Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007;5:415–425

25. Lee MW, Chanda D, Yang J, et al. Regulation of hepatic gluconeogenesis by an ER-bound transcription factor, CREBH. Cell Metab 2010;11:331–339

26. Gasa R, Jensen PB, Berman HK, Brady MJ, DePaoli-Roach AA, Newgard CB. Distinctive regulatory and metabolic properties of glycogen-targeting subunits of protein phosphatase-1 (PTG, GL, GM/RGl) expressed in hepatic cells. Mol Cell Biol 1998;18:1207–1215

27. Printen JA, Brady MJ, Saltiel AR. PTG, a protein phosphatase 1-binding protein with a role in glycogen metabolism. Science 1997;275:1476–1478

28. Greenberg CC, Danos AM, Brady MJ. Central role for protein targeting to glycogen in the maintenance of cellular glycogen stores in 3T3-L1 adipocytes. Mol Cell Biol 2006;26:334–342

29. Niewoehner CB. Distinctive regulatory and metabolic properties of glycogen-targeting subunits of protein phosphatase-1 (PTG, GL, GM/RGl) expressed in hepatocytes. J Biol Chem 2000;275:26396–26403

30. Hubbard MJ, Cohen P. On target with a new mechanism for the regulation of protein phosphorylation. Trends Biochem Sci 1993;18:172–177

31. Gerard RD, Chan L. Adenovirus-mediated gene transfer: strategies and applications in lipoprotein research. Curr Opin Lipidol 1996;7:105–111

32. Nieuwenhuis CB, Nuttall FQ. Glycogen concentration and regulation of synthase activity in rat liver in vivo. Arch Biochem Biophys 1995;328:271–278

33. Shikama H, Yajima M, Ui M. Glycogen metabolism in rat liver during transition from the fed to fasted states. Biochim Biophys Acta 1980;631:278–288

34. Fernández-Novell JM, Roca A, Bellido D, Vilaró S, Guinovart JJ. Translocation and aggregation of hepatic glycogen synthase during the fasted-to-refed transition in rats. Eur J Biochem 1996;238:570–575

35. Armstrong CG, Browne GJ, Cohen P, Cohen PT. PPP1R6, a novel member of the family of glycogen-targeting subunits of protein phosphatase 1. FEBS Lett 1997;418:210–214

36. Doherty MJ, Moorhead G, Morrice N, Cohen P, Cohen PT. Amino acid sequence and expression of the hepatic glycogen-binding (GL)-subunit of protein phosphatase-1. FEBS Lett 1995;375:294–298

37. Browne GJ, Delibegovic M, Keppens S, Stalmans W, Cohen PT. The level of the glycogen targeting regulatory subunit R5 of protein phosphatase 1 is decreased in the livers of insulin-dependent diabetic rats and starved rats. Biochem J 2001;360:449–459

38. Stalmans W, de Wulf H, Hers HG. The control of liver glycogen synthetase phosphorylation by phosphorylase. Eur J Biochem 1971;18:582–587

39. Alemany S, Cohen P. Phosphorylase a is an allosteric inhibitor of the glycogen and microsomal forms of rat hepatic protein phosphatase-1. FEBS Lett 1986;198:194–202

40. Mvumbi L, Doperé F, Stalmans W. The inhibitory effect of phosphorylase a on the activation of glycogen synthase depends on the type of synthase phosphorylation. Biochem J 1989;252:407–416

41. Mvumbi L, Stalmans W. High-affinity binding of glycogen-synthase phophatase to glycogen particles in the liver. Role of glycogen in the inhibition of synthase phosphorylation by phosphorylase a. Biochem J 1987;246:367–374

42. Moorhead G, MacKintosh C, Morrice N, Cohen P. Purification of the hepatic glycogen-associated form of protein phosphatase-1 by microcentrifugation. FEBS Lett 1995;362:101–105

43. Armstrong CG, Doherty MJ, Cohen PT. Identification of the separate domains in the hepatic glycogen-targeting subunit of protein phosphatase 1 that interact with phosphorylase a, glycogen and protein phosphatase 1. Biochem J 1998;336:699–704

44. Kelsall IR, Munro S, Halliburton I, Treadway JL, Cohen PT. The hepatic PPI glycogen-targeting subunit interacts with phosphorylase a can be blocked by C-terminal tyrosine deletion or an indole drug. FEBS Lett 2007;581:4749–4753

45. Pautsch A, Stadler N, Wissdorf O, Langkopf E, Moreth W, Streicher R. Molecular recognition of the protein phosphatase 1 glycogen targeting subunit by glycogen phosphorylase. J Biol Chem 2008;283:8913–8918

46. Hwang JH, Persenghin G, Rothman DL, et al. Impaired net hepatic glycogen synthesis in insulin-dependent diabetic subjects during mixed meal ingestion. A 13C nuclear magnetic resonance spectroscopy study. J Clin Invest 1995;95:783–787

47. Velho G, Petersen KE, Persenghin G, et al. Impaired hepatic glycogen synthesis in insulin-dependent diabetic subjects during mixed meal ingestion. A 13C nuclear magnetic resonance spectroscopy study. J Clin Invest 1995;95:783–787

48. Chen YH, Hansen L, Chen MX, et al. Sequence of the human glycogen-associated regulatory subunit of type 1 protein phosphatase and analysis of its coding region and mRNA level in muscle from patients with NIDDM. Diabetes 1994;43:1234–1241

49. Delibegovic M, Armstrong CG, Dobbie L, Watt SM, Smith AJ, Cohen PT. Disruption of the striated muscle glycogen targeting subunit PPP1R6A of protein phosphatase 1 leads to increased weight gain, fat deposition, and development of insulin resistance. Diabetes 2003;52:606–604

50. Yang R, Newgard CB. Hepatic expression of a targeting subunit of protein phosphatase-1 in streptozotocin-diabetic rats reverses hyperglycemia and hyperphagia despite depressed glucokinase expression. J Biol Chem 2003;278:23418–23425